Nucleic Acid Therapy Accelerator (NATA)

A new class of medicines—built from the genetic molecules DNA and RNA—is being accelerated from lab bench to patient bedside by a dedicated UK hub called the Nucleic Acid Therapy Accelerator (NATA). These therapies work by directly targeting the faulty genes that cause disease, offering a fundamentally different approach from conventional pills or injections. Unlike traditional drugs, which often take a decade or more to develop, nucleic acid therapies can be designed and tested far more quickly—a critical advantage for emerging infectious threats or rare genetic conditions. However, the field faces stubborn scientific hurdles: getting these fragile molecules into the right cells, keeping them stable in the body, and manufacturing them at scale. NATA exists to solve those problems. It brings together chemists, biologists, and engineers to build the shared tools, protocols, and knowledge that the entire field needs. If successful, the accelerator could turn nucleic acid therapies from a promising niche into a reliable platform for treating both rare and common diseases. The impact would be felt not in daily life directly, but in the quiet machinery of drug development—shorter timelines, lower costs, and a faster route from genetic discovery to a working medicine.